Non-Infringement and Claim Construction The Delaware courts decision rested on claim construction, interpreting the #003 patents limitation of administering semaglutide without another therapeutic agent. During prosecution, Novo Nordisk narrowed the claim to a maximum dose of 1.6 mg to secure approval, limiting its scope (Casetext, March 25, 2024)
First, a medicine needs a licensing decision from the MHRA
Protect the medicine from direct sunlight, heat, and moisture
The BBB F rating is a real concern, but it does not undermine the core value proposition for most patients
Central to Chinese medicine is the "holistic view" and "syndrome differentiation and treatment," which assert that depression is closely linked to an individuals physical condition, emotional state, and environmental factors